P1.02-034 EGFR Mutations and ALK Translocations in Lung Cancer - A National Study

Abstract

The Danish Lung Cancer Registry (DLCR) has since 2003 reported all cases of lung cancer in Denmark. Since 2012 data on EGFR mutations and ALK translocations have been included. Little is known on the distribution of EGFR mutations and ALK translocations on a national level in a primarily Caucasian population like the Danish lung cancer population. All Danish lung cancer patients are ascertained based on coded information in the National Patient Register. Supplementary information for each patient is obtained from the clinical units as well as from the National Pathology Register (NPR). Based on SNOMED coding by all departments performing lung cancer pathology evaluation and registered in the NPR the subgroups of lung cancer are identified. The patients are tested for EGFR mutations and ALK translocations according to national guidelines and the results are registered in the NPR. It is estimated that 95 % of all Danish lung cancer patients are present or former smokers and that the sex distribution is equal between the sexes. 4667 patients diagnosed in 2015 are included. Table 1. Distribution of EGFR mutations and ALK translocation in the 2015 lung cancer population: 83.3 % of all patients with lung cancer and adenocarcinoma in Denmark are tested for EGFR mutations and 9.4 % are positive. 73.1 % of adenocarcinomas are tested for ALK translocations and 1.4 % is found to be positive. In total only 8.8 % of all tested lung cancer patients are found to be EGFR mutated and 1.3 % has an ALK translocation. Data from primarily Asian lung cancer populations have shown significant higher rates of EGFR mutations and ALK translocations that the findings in this Danish population. Based on these data the cost-effectiveness of the chosen strategy for reflex testing lung cancer patients up front should be reconsidered.